
Zynerba Pharmaceuticals ZYNE
Quarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals EV/EBITDA Ratio 2011-2026 | ZYNE
Annual EV/EBITDA Ratio Zynerba Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.574 | -0.678 | -1.2 | -0.428 | -2.99 | -5.33 | 0.96 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.96 | -5.33 | -1.46 |
EV/EBITDA Ratio of other stocks in the Drug manufacturers industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
4.15 | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
0.353 | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-18.4 | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
-4.28 | $ 1.27 | 6.72 % | $ 137 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-2.97 | - | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
-14.5 | $ 2.67 | -0.19 % | $ 1.41 B | ||
|
Agile Therapeutics
AGRX
|
-18.5 | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
22.8 | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
1.47 | - | - | $ 50.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-0.0195 | - | -0.1 % | $ 2.03 B | ||
|
Eagle Pharmaceuticals
EGRX
|
160 | - | -39.89 % | $ 27.7 M | ||
|
HEXO Corp.
HEXO
|
-1.44 | - | 2.45 % | $ 38.1 M | ||
|
Endo International plc
ENDP
|
-1.77 | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-27.4 | - | - | $ 36.6 M | ||
|
Emergent BioSolutions
EBS
|
7.77 | $ 13.99 | 0.58 % | $ 716 M | ||
|
Athenex
ATNX
|
-1.1 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-6.92 | $ 21.43 | -0.33 % | $ 2.04 B | ||
|
Evolus
EOLS
|
-9.74 | $ 5.66 | 0.03 % | $ 351 M | ||
|
Harrow Health
HROW
|
72.8 | $ 50.22 | -1.54 % | $ 1.64 B | ||
|
China Pharma Holdings
CPHI
|
51.8 | $ 1.58 | 17.04 % | $ 27.6 M | ||
|
Jupiter Wellness
JUPW
|
-50.5 | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
-2.79 | $ 1.72 | 2.08 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
18.6 | $ 7.89 | -0.25 % | $ 2.88 B | ||
|
Pacira BioSciences
PCRX
|
29.6 | $ 26.1 | 0.38 % | $ 1.21 B | ||
|
Lannett Company
LCI
|
-3.47 | - | 1.15 % | $ 7.11 M | ||
|
Rockwell Medical
RMTI
|
-13.7 | $ 0.98 | 3.51 % | $ 22.9 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-19.4 | $ 4.88 | -5.97 % | $ 68.6 M | ||
|
Neoleukin Therapeutics
NLTX
|
0.202 | - | - | $ 193 M | ||
|
Sundial Growers
SNDL
|
-1.27 | $ 1.66 | 0.61 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-4.16 | $ 3.78 | 0.27 % | $ 4.69 M | ||
|
Organogenesis Holdings
ORGO
|
15.8 | $ 4.26 | -0.81 % | $ 561 M | ||
|
Aurora Cannabis
ACB
|
-2.99 | $ 4.29 | 1.06 % | $ 86.3 M | ||
|
PetIQ
PETQ
|
9.82 | - | 1.64 % | $ 400 M | ||
|
Veru
VERU
|
31.2 | $ 2.31 | -2.53 % | $ 312 M | ||
|
Recro Pharma
REPH
|
13.4 | - | -4.76 % | $ 65.3 M | ||
|
Perrigo Company plc
PRGO
|
11.2 | $ 14.83 | 1.61 % | $ 2.04 B | ||
|
ProPhase Labs
PRPH
|
9.86 | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-13.2 | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
-2.7 | $ 1.06 | -4.93 % | $ 4.57 M | ||
|
Relmada Therapeutics
RLMD
|
-2.91 | $ 4.31 | -0.35 % | $ 130 M | ||
|
OptiNose
OPTN
|
-2.04 | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
7.11 | $ 9.42 | -0.11 % | $ 669 M | ||
|
PLx Pharma
PLXP
|
-1.81 | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
-0.17 | $ 5.46 | -2.76 % | $ 223 M | ||
|
SCYNEXIS
SCYX
|
-1.32 | $ 0.65 | 1.26 % | $ 31.1 M | ||
|
Tricida
TCDA
|
-3.32 | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
-46 | $ 9.12 | 1.39 % | $ 5.64 B | ||
|
TherapeuticsMD
TXMD
|
-45.5 | $ 2.01 | -1.47 % | $ 21 M | ||
|
Viatris
VTRS
|
10.5 | $ 12.53 | 0.52 % | $ 15.2 B | ||
|
Zomedica Corp.
ZOM
|
8.79 | - | -0.21 % | $ 98 M |